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BACKGROUND: The Genetics of Subsequent Coronary Heart Disease 
(GENIUS-CHD) consortium was established to facilitate discovery and 
validation of genetic variants and biomarkers for risk of subsequent CHD 
events, in individuals with established CHD.
METHODS: The consortium currently includes 57 studies from 18 
countries, recruiting 185 614 participants with either acute coronary 
syndrome, stable CHD, or a mixture of both at baseline. All studies 
collected biological samples and followed-up study participants 
prospectively for subsequent events.
RESULTS: Enrollment into the individual studies took place between 1985 
to present day with a duration of follow-up ranging from 9 months to 
15 years. Within each study, participants with CHD are predominantly of 
self-reported European descent (38%–100%), mostly male (44%–91%) 
with mean ages at recruitment ranging from 40 to 75 years. Initial 
feasibility analyses, using a federated analysis approach, yielded expected 
associations between age (hazard ratio, 1.15; 95% CI, 1.14–1.16) per 
5-year increase, male sex (hazard ratio, 1.17; 95% CI, 1.13–1.21) and 
smoking (hazard ratio, 1.43; 95% CI, 1.35–1.51) with risk of subsequent 
CHD death or myocardial infarction and differing associations with other 
individual and composite cardiovascular endpoints.
CONCLUSIONS: GENIUS-CHD is a global collaboration seeking to 
elucidate genetic and nongenetic determinants of subsequent event risk 
in individuals with established CHD, to improve residual risk prediction 
and identify novel drug targets for secondary prevention. Initial analyses 
demonstrate the feasibility and reliability of a federated analysis approach. 
The consortium now plans to initiate and test novel hypotheses as well as 
supporting replication and validation analyses for other investigators.
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Major public health initiatives and policy chang-es, along with advances in drug and inter-ventional therapies have significantly reduced 
cardiovascular morbidity and mortality in most high-in-
come countries.1–3 However, the improved survival rates 
following an initial presentation with coronary heart 
disease (CHD) has, paradoxically, led to a growing num-
ber of patients living with established CHD (eg, 16M 
in the United States and 3M in the United Kingdom)4,5 
who remain at substantially high risk of subsequent car-
diovascular events. These include myocardial infarction 
(MI), repeated revascularizations but also heart failure, 
stroke, and sudden death.4
Despite a large body of knowledge on the patho-
physiology of first CHD events in general populations,6,7 
little is known about factors that influence disease pro-
gression or subsequent events in patients with estab-
lished CHD, beyond those consequent to the acute 
index event in the short-term (such as biomarkers of 
myocardial dysfunction or necrosis, left ventricular func-
tion, or arrhythmia).8 As a result, although guidelines 
and treatment thresholds have progressively evolved 
over the past 2 decades, the targeted risk factors per 
se have remained largely unaltered.9 Novel therapies 
beyond lipid lowering, antiplatelet agents, and drugs 
recommended for high blood pressure and heart fail-
ure have been slow to emerge. Importantly, multiple 
novel and existing agents (eg, darapladib, varespladib, 
and folic acid) have failed in very late stage clinical 
development despite promising observational data.10–13 
In contrast, some traditional risk factors, such as obe-
sity, which show robust associations with initial CHD 
onset,14 continue to show inverse or null associations 
with subsequent events once CHD has developed.15
Ultimately, the high (residual) risk in individuals with 
existing CHD despite optimal contemporary therapy 
emphasizes the need for studying risk of subsequent 
events and their related causal pathways. For exam-
ple, in the intervention arm of the IMPROVE-IT study 
(Vytorin Efficacy International Trial), despite simvastatin 
and ezetimibe treatment following an acute coronary 
syndrome, at 7 years, almost a third of participants 
experienced the primary end point (a composite of 
cardiovascular death, major coronary event, coronary 
revascularization, or nonfatal stroke).16 Similarly, in 
the FOURIER trial (Further Cardiovascular Outcomes 
Research with PCSK9 [proprotein convertase subtilisin-
kexin type 9] Inhibition in Subjects with Elevated Risk), 
almost 10% of patients with established but stable 
CVD, experienced an event at 2.2 years despite high-
intensity statin and PCSK9 inhibition, with achieved 
median LDL-C (low-density lipoprotein cholesterol) lev-
els of 30 mg/dL.17 These data point to the existence of 
risk factors beyond traditional ones such as LDL-C, and 
the need to elucidate their related causal pathways.18 
By studying those with established CHD at high risk of 
subsequent events, we plan to gain novel insights into 
other drivers of atherosclerosis or features that identify 
patients who may benefit most from novel therapies.9 
Genetic and biomarker studies in these individuals may 
help identify novel molecular pathways and future drug 
targets with the goal of advancing precision medicine.
In the absence of a single-large resource to study 
the determinants of coronary heart disease prognosis, 
we have established the Genetics of Subsequent CHD 
(GENIUS-CHD) consortium.19 Assembling studies from 
across the globe that have recruited patients with dif-
ferent types of CHD at baseline, have acquired prospec-
tive follow-up, and have stored biological specimens, 
or genetic data, the consortium aims to: (1) investigate 
genetic and nongenetic determinants of risk for subse-
quent CHD, systematically and at scale and (2) facilitate 
access to data and expertise, as a platform to foster 
collaboration among investigators working in the field.
Here, we describe the design of the consortium, 
including details of participating studies, available data, 
and samples, as well as the governance procedures and 
the consortium’s approach to data sharing and collabo-
ration to further advance the stated scientific aims. In 
addition, we present some early findings from an inves-
tigation of the association of patient characteristics and 
certain routinely recorded measures on the risk of sub-
sequent events among patients with different types of 
CHD at baseline.
METHODS
In accordance with Transparency and Openness Promotion 
Guidelines, the data, analytic methods, and study materi-
als will be made available to other researchers for purposes 
of reproducing the results or replicating the procedures. 
Participating studies received local institutional review board 
approval and included patients who had provided informed 
consent at the time of enrollment. The central analysis sites 
also received waivers from their local institutional review 
board for collating and analyzing summary-level data from 
these individual studies. Full details on the eligibility criteria, 
definitions of terminology, management of the consortium, 
and planned projects are provided in Materials in the Data 
Supplement.
RESULTS
The design and structure of the GENIUS-CHD consor-
tium are presented in Figure  1. Studies meeting the 
main eligibility criteria were identified and invited to 
participate (Methods in the Data Supplement). In brief, 
studies are eligible to join the GENIUS-CHD consortium 
if they meet 3 inclusion criteria: (1) included individuals 
with established CHD (defined as the presence of or 
confirmed history of acute coronary syndrome at base-
line, or of coronary artery disease as evidenced by any 
revascularization procedure (percutaneous coronary 
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
Patel et al; Design and Rationale of GENIUS-CHD
Circ Genom Precis Med. 2019;12:e002470. DOI: 10.1161/CIRCGEN.119.002470 April 2019 147
intervention or bypass surgery) or demonstrable plaque 
in any epicardial vessel on direct coronary imaging); 
(2) acquired prospective follow-up of participants with 
ascertainment of one or more subsequent cardiovascu-
lar disease events as well as all-cause mortality; and (3) 
had stored blood samples, which are viable and suitable 
for DNA and biomarker analysis or previously collected 
such data before sample depletion.
At the time of writing, 57 studies from 18 coun-
tries are participating in the consortium and are listed 
in Table 1. Please refer to www.genius-chd.org for an 
updated list. Brief narrative descriptions of each study 
are provided in Methods in the Data Supplement.
The majority of studies are either investigator-led 
clinical cohorts (n=42), but clinical trials (n=10) and 
nested case-cohort (inception-study design) studies 
(n=5) are also included. Of the total, 23 studies have 
included participants at the time of an acute coronary 
syndrome, while the remainder recruited those with 
stable CHD or a mixture of the 2 (eg, from cardiac cath-
eterization labs). Collectively, 185 614 participants have 
been enrolled with CHD at baseline (including 812 803 
person-years of follow-up); of which 170 343 are of self-
reported European descent. Recruitment times varied 
between studies, ranging from the earliest recruitment 
in 1985 to studies that remain actively recruiting to the 
present day. All studies enrolled patients >18 years of 
age, although one study exclusively recruited only those 
with premature CHD (MI <45 years), while another 
recruited only older subjects (>70 years). The overall 
mean age within each study reflects this heterogeneity, 
ranging from 40 to 75 years of age, and proportion of 
male sex ranging from 44% to 91% (Table 1).
Available Data
Core Phenotypes
All studies collected data on age, sex, and ethnicity. Risk 
factor data are available for diabetes mellitus, obesity, 
and smoking status in almost all participating studies 
(96%), while data on concentrations of routine blood 
lipids (total cholesterol, LDL-C, HDL-C [high-density 
lipoprotein cholesterol], and triglycerides; 84%), and 
blood pressure values at enrollment (82%) were col-
lected by the majority of studies. Data on statin use at 
baseline are available in 90% of all participating studies 
(Table 2).
Figure 1. Overview of the Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium, illustrating inclusion criteria and governance 
structure.  
Following project approval by the steering committee, analyses scripts are prepared and distributed to all members, with sharing of summary-level outputs before 
meta-analysis at the coordinating centers. Further details can be found at www.genius-chd.org. QC indicates quality control.
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Additional Phenotypes
A list of selected additional phenotypes available by 
study is presented in Table I in the Data Supplement. Of 
note, 79% have available data on plasma CRP (C-reac-
tive protein), while coronary disease burden informa-
tion, from invasive angiography is available in 52% of 
studies. Finally, over a third of studies have also collect-
ed data on physical activity (38%) and socioeconomic 
status (37%).
Samples
Stored samples are available in most studies for future 
assay testing and stored frozen. The majority have stored 
plasma (75%), while others also have serum, blood 
EDTA, RNA, and urine (Table II in the Data Supplement).
DNA and Genotyping
More than two-thirds of the studies have DNA still avail-
able, either preextracted or as whole blood collected 
in EDTA and stored for future genotyping. All studies 
within the consortium have performed genotyping in 
some capacity, with genome-wide data available in a 
subset of studies (Table III in the Data Supplement).
Subsequent Events and Follow-Up
The most commonly collected end point was all-cause 
death, collected by all but 2 studies. CHD death during 
follow-up was collected in 70% of studies, while inci-
dent MI was reported by 82% of studies. Studies ascer-
tained end points through different means, including 
telephone contact, in-person patient interviews, clinical 
chart reviews, and linkage to national mortality registers 
and hospital records (Table IV in the Data Supplement).
Power Calculations
Empirical power was estimated based on a conservative 
sample size of 150 000 subjects with an event rate of 
10% (across the entire follow-up period with a mean 
of about 5 years); Figure 2. Given that the GENIUS-CHD 
consortium is designed to answer multiple questions, 
power was estimated for a range of genetic single 
nucleotide polymorphisms (SNPs) and nongenetic (bio-
markers and clinical risk factors) effects.
Minor allele frequencies of 0.01, 0.05, 0.10, and 
0.25 were examined, representing rare to common 
SNPs. For each minor allele frequency, power was calcu-
lated for a range of plausible SNP effects on biomarkers 
(mean difference [μ] 0.01, 0.03, and 0.05) and clinical 
end points (odds ratios of 1.02, 1.05, and 1.10). For 
the association of SNPs with biomarkers, power was 
80% (α=0.05) or more unless the SNP was rare (minor 
allele frequency of 0.01) or the effect size was small 
(eg, 0.01 per allele). For the association of SNPs with 
clinical end points, power was close to 80% when the 
effect size was large (odds ratio ≥1.10) or the minor 
allele frequency was ≥0.10.
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Power of observational (ie, nongenetic) analysis was 
>99% for both continuous and binary exposures unless 
the odds ratio was close to 1. In addition to continu-
ous and binary outcome data, GENIUS-CHD also collects 
time-to-event data. Given the similarity (in most empiri-
cal settings) between odds ratio and hazard ratios,20 sim-
ilar power is to be expected for time-to-event analysis.
Initial Analysis
To examine the feasibility of the federated analysis 
approach, we sought to collect data on participant char-
acteristics, cardiovascular and mortality outcomes and 
association analyses with common clinical exposures. A 
standardized dataset was developed, with a federated 
analysis conducted using standardized statistical scripts. 
The summary-level outputs generated were then shared 
with the coordinating centers for aggregating and meta-
analysis (Methods in the Data Supplement).
Participant Characteristics
Detailed characteristics of participants by study are pre-
sented in Table 2. Prevalence of risk factors varied by 
study, with diabetes mellitus ranging from 4% to 76%; 
smoking from 8% to 79%. Mean total cholesterol by 
study ranged from 166.3 to 239.8 mg/dL, mean body 
mass index ranged from 24.8 to 30.2 kg/m2 and mean 
systolic blood pressure from 117 to 153 mm Hg. The 
proportion of participants with prior revascularization 
or MI was high in most studies reflecting the inclusion 
criteria for the consortium (Table 2).
Review of returned outputs from the federated anal-
ysis revealed good quality data with estimates falling 
within expected ranges for age, sex, and other vari-
ables, such as body mass index (Figure I in the Data 
Supplement).
Figure 2. Figure illustrating empirical power for detecting different effect sizes for biomarker variance and clinical events for both α 0.05 and 
0.0001, by varying minor allele frequencies, for a conservative total number of 150 000 with an event rate of 10%.  
MAF indicates minor allele frequency; and OR, odds ratio.
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End Points
The primary end point preselected for the study was 
a composite of coronary death or MI (CHD death/
MI). Mean follow-up was estimated in each study and 
ranged between 9 months and 15 years. In total, we 
estimated over 748 000 person-years of follow-up were 
available for the primary end point analysis.
Information was collected on 10 subsequent event 
end points in the initial feasibility analysis. Across all 
studies, the most frequently occurring event during 
prospective follow-up was the composite of all cardio-
vascular events (27%); followed by revascularization 
(21.8%); all-cause mortality (15%); coronary death or 
MI (14.2%); MI (10.7%); cardiovascular death (8.3%); 
coronary death (8%); heart failure (6.3%); all stroke 
(3.6%); and ischemic stroke (3.4%).
Association Analyses
As a feasibility analysis, we examined associations 
between age, male sex, and smoking with the primary 
end point CHD death/MI as well as with the 9 other 
secondary end points, to investigate any differential 
associations across discrete subsequent events.
In analyses unrestricted by race or type of CHD at 
baseline, but adjusted for sex, there was a strong asso-
ciation between each 5-year increment in age with sub-
sequent risk of the primary end point of CHD death/
MI (hazard ratio [HR] 1.15; 95% CI, 1.14–1.16). The 
largest observed HRs were for all-cause mortality (HR, 
1.36; 95% CI, 1.35–1.37), cardiovascular death (HR, 
1.36; 95% CI, 1.35–1.38), and heart failure (HR, 1.25; 
95% CI, 1.24–1.27), while a smaller risk increase was 
observed for MI (HR, 1.06; 95% CI, 1.05–1.07). The risk 
of future revascularization, however, showed a modest 
inverse association with increasing age (HR, 0.98; 95% 
CI, 0.98–0.99; Figure 3).
Male sex was a risk factor for CHD death/MI (HR, 
1.17; 95% CI, 1.13–1.21) and other coronary and mor-
tality end points (Figure 4) after adjustment for age. In 
particular, the largest observed HR was for risk of revas-
cularization, which was considerably higher in males 
(HR, 1.24; 95% CI, 1.20–1.27). In contrast, there was 
no strong evidence for an association between male sex 
and risk of stroke (ischemic or any stroke; Figure 4).
Finally, in analyses adjusted for age and sex, cur-
rent smoking (compared to prior or never smoking) at 
the time of enrollment showed a strong association 
with risk of future CHD death/MI (HR, 1.43; 95% CI, 
1.35–1.51). Similarly, smoking was associated with an 
increased risk of all-cause mortality (HR, 1.53; 95% CI, 
1.47–1.58) and an increased risk of all other end points, 
although there was no strong evidence for an associa-
tion with incident revascularization (HR, 1.02; 95% CI, 
0.99–1.05; Figure 5).
When stratified by type of CHD at enrollment, that 
is, among those presenting with an acute event, those 
with stable CAD without ever having had an MI and 
those with stable CAD and a prior MI, the findings 
were similar and directionally concordant to nonstrati-
fied analyses described above, for all end points (data 
not shown).
Figure 3. Meta-analyses of the associations 
between age (per 5-year intervals) and 
different end points, adjusted for sex. Esti-
mates are presented as hazard ratios (HRs) with 
95% CI. CHD indicates coronary heart disease; 
CVD, cardiovascular disease; and MI myocardial 
infarction.
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DISCUSSION
The GENIUS-CHD Consortium is a global collaborative 
effort engaging 57 studies, including almost 185 000 
patients with established CHD, for whom genetic 
and prospective follow-up data are available. It brings 
together over 170 domain experts, including clinicians, 
data scientists, geneticists, and epidemiologists, all 
engaged in improving our understanding of the deter-
minants of subsequent event risk in these patients. 
With an agreed governance structure and a proven 
federated analysis approach, we anticipate that this 
consortium will be a valuable long-term resource for 
genetic and nongenetic research in this field.
Genetic association studies for CHD disease progres-
sion, recurrence, and adverse events after a CHD event 
may have particular utility for identifying novel causal 
pathways and therapeutic targets that may be different 
than those for first events, a concept recently supported 
by research in other disease areas.21 However, informa-
Figure 4. Meta-analyses of the associations 
between male sex and different end points, 
adjusted for age.  
Estimates are presented as hazard ratios (HRs) 
with 95% CI. CHD indicates coronary heart 
disease; CVD, cardiovascular disease; and MI, 
myocardial infarction.
Figure 5. Meta-analyses for the associa-
tions between smoking at coronary heart 
disease (CHD) indexing event compared to 
not smoking and for different end points, 
adjusted for age and sex.  
Estimates are presented as hazard ratios (HRs) 
with 95% CI. CVD indicates cardiovascular 
disease; and MI, myocardial infarction.
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tion on the determinants of subsequent CHD event risk 
is scarce, in contrast to the extensive knowledge about 
risk factors for a first CHD event. This disparity is due, 
in part, to the relatively small sample sizes of individual 
studies in the secondary prevention setting. While larg-
er registry and electronic health care records efforts will 
result in higher numbers, they typically suffer from the 
lack of necessary depth of phenotyping, accuracy, and 
availability of biospecimens to infer further biological 
insights.22,23 In contrast, large population studies with 
detailed phenotyping have relatively small numbers of 
mostly stable CHD patients, who have survived many 
years after their index event.24,25 By bringing together 
multiple investigator-led studies, the GENIUS-CHD con-
sortium aims to address and overcome this major limi-
tation to subsequent CHD risk research.
Importantly, the scale and depth of the GENIUS-CHD 
consortium offer greater scope to tackle key challenges 
within subsequent CHD risk-related research. First, CHD 
is a heterogeneous phenotype, consisting of stable, 
unstable, and pathologically distinct subtypes, which 
have often been combined for individual studies to 
satisfy the need for statistical power. With the sample 
size available in GENIUS-CHD, we anticipate being able 
to disaggregate CHD into more precise subphenotypes 
such as acute versus stable CHD at baseline, or those 
with versus without prior MI, which may help uncover 
relevant biological differences.26 Additional stratifica-
tion on variables such as sex, time period of recruitment, 
duration of follow-up, country of study, LV function and 
treatment (such as statin, blood pressure lowering, and 
antiplatelet agent use) will also be possible, providing 
greater insights into the modifying influences of these 
variables on outcome.
A major strength of the consortium is the use of a 
federated analysis approach that permits individual lev-
el analysis without the need for sharing either samples 
or the individual datasets themselves, thereby overcom-
ing major privacy and governance hurdles. The effort 
has been successful because (1) participation is entirely 
voluntary, with studies only participating in those analy-
ses they feel are of value, or to which they have the 
capacity to contribute; (2) ownership of all data and 
samples remain with the principal investigator and are 
not shared nor stored centrally; and (3) there are open 
and transparent governance procedures. Our feasibility 
analysis has demonstrated that this federated approach 
works well and yields results that are consistent and 
suitable for high-quality meta-analysis.
Indeed, supported by this initial feasibility analysis, 
our findings demonstrate the validity of the data col-
lected by confirming the anticipated associations of 
increasing age, male sex, and current smoking with 
higher risks of subsequent CHD death/MI during follow-
up. Furthermore, by exploring multiple individual and 
composite end points, we can begin to unravel associa-
tions not discoverable in smaller studies. For example, 
we find that the risk of incident revascularization is low-
er with advancing age but higher for male sex and neu-
tral for smoking. Plausible explanations may exist for 
each of these findings (eg, an association induced by 
clinical practice, with fewer older people being offered 
invasive treatments), but importantly they highlight the 
value of exploring multiple end points at an appropriate 
scale. This is especially relevant when exploring novel 
biomarkers or drug targets as these may, in turn, be 
used to inform clinical testing strategies and choice of 
end points to study in trials.
By virtue of the expertise it has assembled, the 
consortium is also well placed to address important 
methodological issues surrounding prognosis research 
in general. For example, selection bias is a key con-
cern, whereby it is conceivable that those at highest 
risk may die early and not enter any of the member 
studies for evaluation (survival bias), or selection on an 
indexing event itself may distort patient characteristics 
and impact association findings (index event bias).27 
In addition, treatment effects may alter the trajectory 
of disease by stabilizing or regressing plaque burden 
or altering baseline risk, such as with high-dose statin 
or PCSK9 inhibitor use.17,28 To address these and other 
issues, the consortium has established working groups 
of relevant national and international experts to explore 
the extent and impact of such biases/effects and if 
needed, to develop approaches to address these.29
There are inherent challenges to overcome when 
working with diverse multiple studies, including varia-
tions in definitions and processes for data collection 
and curation across different studies in different centers 
and different countries. The consortium members have 
attempted to standardize common data elements, for 
example, the measurement units for quantitative traits. 
Variability between studies will persist, but we antici-
pate that the overall size of the effort will help reduce 
the impact of such study level heterogeneity on any 
findings, which will also be explored through subgroup 
analyses where possible (eg, country, study size, and year 
of first recruitment). Analytical challenges will addition-
ally include dealing with variability in length of follow-
up across studies, handling multiple subsequent events 
along with competing risks, as well as confounding by 
treatment and selection biases as described above. The 
collective experience of the consortium members will 
be leveraged to address these as carefully as possible 
within each future analysis. Finally, factors influencing 
enrollment into genetic studies of CHD may limit the 
generalizability of findings. Men are over represented in 
participating CHD studies, partly reflecting sex-differen-
tial prevalence of disease but also underpinning a wider 
concern about underinvestigation of women, who may 
be inadvertently excluded given that entry criteria for 
most studies relies on documented presence of CHD. 
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Similarly, many studies in the consortium have recruited 
mostly Europeans, limiting the opportunity to explore 
hypotheses in other ethnic groups. The steering com-
mittee is conscious of these imbalances and is actively 
seeking studies enriched for women and non-Europe-
an participants to join the collaboration. In summary, 
the GENIUS-CHD consortium is a global collaboration 
among investigators who have recruited patients with 
CHD into multiple individual studies, seeking to gain 
a better understanding of subsequent CHD event risk 
and enhance secondary prevention. It seeks to be an 
open, collegiate, and transparent effort and we invite 
investigators with suitable studies to join and collective-
ly enhance research efforts in this domain.
ARTICLE INFORMATION
Received February 4, 2019; accepted March 18, 2019.
The Data Supplement is available at https://www.ahajournals.org/doi/ 
suppl/10.1161/CIRCGEN.119.002470.
Authors
Riyaz S. Patel, MD*; Vinicius Tragante, PhD*; Amand F. Schmidt, PhD*; Ray-
mond O. McCubrey, MS; Michael V. Holmes, MD, PhD; Laurence J. Howe, PhD; 
Kenan Direk, PhD; Axel Åkerblom, MD, PhD; Karin Leander, PhD; Salim S. Vi-
rani, MD, PhD; Karol A. Kaminski, MD, PhD; Jochen D. Muehlschlegel, MD, 
MMSc; Hooman Allayee, PhD; Peter Almgren, MSc; Maris Alver, MSc; Ekaterina 
V. Baranova, MSc; Hassan Behloui, PhD; Bram Boeckx, PhD; Peter S. Braund, 
PhD; Lutz P. Breitling, MD; Graciela Delgado, MSc; Nubia E. Duarte, PhD; 
Marie-Pierre Dubé, PhD; Line Dufresne, MSc; Niclas Eriksson, PhD; Luisa Foco, 
PhD; Markus Scholz, PhD; Crystel M. Gijsberts, MD, PhD; Charlotte Glinge, 
MD; Yan Gong, PhD; Jaana Hartiala, PhD; Mahyar Heydarpour, PhD; Jaroslav A. 
Hubacek, DSc; Marcus Kleber, PhD; Daniel Kofink, PhD; Salma Kotti, PharmD, 
PhD; Pekka Kuukasjärvi, PhD; Vei-Vei Lee, MS; Andreas Leiherer, PhD; Petra A. 
Lenzini, MS; Daniel Levin, PhD; Leo-Pekka Lyytikäinen, MD; Nicola Martinelli, 
MD, PhD; Ute Mons, PhD; Christopher P. Nelson, PhD; Kjell Nikus, PhD; Anna 
P. Pilbrow, PhD; Rafal Ploski, MD, PhD; Yan V. Sun, PhD; Michael W.T. Tanck, 
PhD; W.H.Wilson Tang, MD; Stella Trompet, PhD; Sander W. van der Laan, PhD; 
Jessica Van Setten, PhD; Ragnar O. Vilmundarson, MSc; Chiara Viviani Anselmi, 
PhD; Efthymia Vlachopoulou, PhD; Lawien Al Ali, MD; Eric Boerwinkle, PhD; 
Carlo Briguori, MD, PhD; John F. Carlquist, PhD; Kathryn F. Carruthers, MPhil; 
Gavino Casu, MD; John Deanfield, MD; Panos Deloukas, PhD; Frank Dudbridge, 
PhD; Thomas Engstrøm, MD, PhD; Natalie Fitzpatrick, MSc; Kim Fox, MD, PhD; 
Bruna Gigante, PhD; Stefan James, MD, PhD; Marja-Liisa Lokki, PhD, Paulo A. 
Lotufo, MD, PhD; Nicola Marziliano, PhD; Ify R. Mordi, MD; Joseph B. Muhles-
tein, MD; Christopher Newton-Cheh, MD; Jan Pitha, PhD; Christoph H. Saely, 
MD; Ayman Samman-Tahhan, MD; Pratik B. Sandesara, MD; Andrej Teren, MD; 
Adam Timmis, MD; Frans Van de Werf, PhD; Els Wauters, PhD; Arthur A.M. 
Wilde, MD, PhD; Ian Ford, MD, PhD; David J. Stott, MD; Ale Algra, MD; Ma-
ria G. Andreassi, PhD; Diego Ardissino, MD; Benoit J. Arsenault, PhD; Christie 
M. Ballantyne, MD; Thomas O. Bergmeijer, MD; Connie R. Bezzina, PhD; Si-
mon C. Body, MBChB, MPH; Eric H. Boersma, MD, PhD; Peter Bogaty, MD; 
Michiel L. Bots, MD; Hermann Brenner, MD, PhD; Jasper J. Brugts, MD, PhD; 
Ralph Burkhardt, MD; Clara Carpeggiani, MD; Gianluigi Condorelli, MD, PhD; 
Rhonda M. Cooper-DeHoff, PharmD; Sharon Cresci, MD; Nicolas Danchin, MD, 
PhD; Ulf de Faire, PhD; Robert N. Doughty, MD; Heinz Drexel, MD; James C. 
Engert, PhD; Keith A.A. Fox, MD, PhD; Domenico Girelli, MD, PhD; Diederick 
E. Grobbee, MD, PhD; Emil Hagström, MD, PhD; Stanley L. Hazen, MD, PhD; 
Claes Held, MD, PhD; Harry Hemingway, MD, PhD; Imo E. Hoefer, MD, PhD; 
G. Kees Hovingh, MD, PhD; Reza Jabbari, MD, PhD; Julie A. Johnson, PharmD; 
J. Wouter Jukema, MD, PhD; Marcin P. Kaczor, MD, PhD; Mika Kähönen, PhD; 
Jiri Kettner, PhD; Marek Kiliszek, MD, PhD; Olaf H. Klungel, PharmD, PhD; Bo 
Lagerqvist, MD, PhD; Diether Lambrechts, PhD; Jari O. Laurikka, PhD; Terho 
Lehtimäki, PhD; Daniel Lindholm, MD, PhD; B. K. Mahmoodi, MD, PhD; Anke 
H. Maitland-van der Zee, PharmD, PhD; Ruth McPherson, MD, PhD; Olle Me-
lander, MD, PhD; Andres Metspalu, MD, PhD; Anna Niemcunowicz-Janica, MD, 
PhD; Oliviero Olivieri, MD; Grzegorz Opolski, MD, PhD; Colin N. Palmer, PhD; 
Gerard Pasterkamp, MD, PhD; Carl J. Pepine, MD; Alexandre C. Pereira, MD, 
PhD; Louise Pilote, MD; Arshed A. Quyyumi, MD; A. Mark Richards, MD, PhD; 
Marek Sanak, MD, PhD; Agneta Siegbahn, MD, PhD; Tabassome Simon, MD, 
PhD; Juha Sinisalo, MD, PhD; J. Gustav Smith, MD, PhD; John A. Spertus, MD, 
MPH; Steen Stender, MD, DSc; Alexandre F.R. Stewart, PhD; Wojciech Szczek-
lik, MD, PhD; Anna Szpakowicz, MD, PhD; Jean-Claude Tardif, MD; Jurriën M. 
ten Berg, MD, PhD; Jacob Tfelt-Hansen, MD, DMSc; George Thanassoulis, MD; 
Joachim Thiery, MD; Christian Torp-Pedersen, MD, DSc; Yolanda van der Graaf, 
MD; Frank L.J. Visseren, MD; Johannes Waltenberger, MD; Peter E. Weeke, 
MD, PhD; Pim Van der Harst, MD, PhD; Chim C. Lang, MD; Naveed Sattar, 
PhD; Vicky A. Cameron, PhD; Jeffrey L. Anderson, MD; James M. Brophy, MD; 
Guillaume Pare, MD; Benjamin D. Horne, PhD, MPH; Winfried März, MD; Lars 
Wallentin, MD, PhD; Nilesh J. Samani, MD, PhD†; Aroon D. Hingorani, MD, 
PhD†; Folkert W. Asselbergs, MD, PhD†
Correspondence
Riyaz S. Patel, Institute of Cardiovascular Sciences, University College London, 
222 Euston Rd, London NW1 2DA, United Kingdom, Email riyaz.patel@ucl.
ac.uk or Folkert W. Asselbergs, Division of Heart and Lungs, Department of 
Cardiology, University Medical Center Utrecht, 3508GA Utrecht, the Nether-
lands, Email f.w.asselbergs@umcutrecht.nl
Affiliations
Institute of Cardiovascular Science (R.S.P., A.F.S., L.J.H., K.D., J.D., A.D.H., 
F.W.A) and Institute of Health Informatics (N.F., A. Timmis, H.H., F.W.A.),  Faculty 
of Population Health Science, University College London, United Kingdom. 
Bart’s Heart Centre, St Bartholomew’s Hospital, London (R.S.P., J.D., A. Timmis). 
Division of Heart and Lungs, Department of Cardiology (V.T., A.F.S.,D.K.,F.W.A.), 
Laboratory of Experimental Cardiology (C.M.G.), Department of Clinical Chem-
istry and Hematology (I.E.H.), and Department of Clinical Chemistry (G.P.), UMC 
Utrecht, the Netherlands. Intermountain Heart Institute, Intermountain Medical 
Center, Salt Lake City, UT (R.O.M., J.F.C., J.B.M., J.L.A., B.D.H). Clinical Trial 
Service Unit and Epidemiological Studies Unit, Nuffield Department of Popula-
tion Health, Medical Research Council Population Health Research Unit, Univer-
sity of Oxford, United Kingdom (M.V.H). National Institute for Health Research 
Oxford Biomedical Research Centre, Oxford University Hospital, United King-
dom (M.V.H.). Uppsala Clinical Research Center, Sweden (A. Åkerblom, N.E., 
S.J., C.H., B.L., D. Lindholm, A. Siegbahn, L.W.). Division of Cardiology, Depart-
ment of Medical Sciences (A. Åkerblom, C.H., D. Lindholm, S.J., B.L., L.W.) and 
Division of Clinical Chemistry, Department of Medical Sciences (A. Siegbahn), 
Uppsala University, Sweden. Institute of Environmental Medicine, Karolinska 
Institute, Stockholm, Sweden (K.L., B.G., U.d.F.). Section of Cardiology, Michael 
E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.S.V.). Section of 
Cardiovascular Research, Department of Medicine, Baylor College of Medicine, 
Houston, TX (S.S.V., C.M.B.). Department of Population Medicine and Civiliza-
tion Disease Prevention (K.A.K.) and Department of Cardiology (K.A.K., A. Sz-
pakowicz), Medical University of Bialystok, Poland. Department of Anesthesiol-
ogy, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston, 
MA (J.D.M., M.H.). Harvard Medical School, Boston, MA (J.D.M., M.H., S.C.B). 
Departments of Preventive Medicine and Biochemistry and Molecular Medicine 
(H.A., J.H.) and Institute for Genetic Medicine (J.H.), Keck School of Medicine of 
USC, Los Angeles, CA. Department of Clinical Sciences, Lund University, 
Malmö, Sweden (P.A., O.M.). Estonian Genome Centre, Department of Bio-
technology, Institute of Genomics, Institute of Molecular and Cell Biology, Uni-
versity of Tartu, Estonia (M.A., A.M.). Division of Pharmacoepidemiology and 
Clinical Pharmacology, Utrecht University, the Netherlands (E.V.B., O.H.K., 
A.H.M.-v.d.Z.). Centre for Outcomes Research and Evaluation, Research Insti-
tute of the McGill University Health Centre, Montreal, QC, Canada (H.B., L.D., 
L.P., G.T., J.M.B.). Research Institute of the McGill University Health Centre, 
Montreal, QC, Canada (J.C.E.). Laboratory for Translational Genetics, Depart-
ment of Human Genetics (B.B., D. Lambrechts) and Department of Cardiovas-
cular Sciences (F.V.d.W.), Katholieke Universiteit Leuven, Belgium. Laboratory 
for Translational Genetics, VIB Center for Cancer Biology, Belgium (B.B., D. 
Lambrechts). Department of Cardiovascular Sciences, BHF Cardiovascular Re-
search Centre, University of Leicester, United Kingdom (P.S.B., C.P.N., N.J.S.). 
NIHR Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom 
(P.S.B., C.P.N., N.J.S.). Division of Clinical Epidemiology and Aging Research, 
German Cancer Research Center (DKFZ), Heidelberg (L.P.B., U.M.). Fifth Depart-
ment of Medicine, Medical Faculty Mannheim, Heidelberg University, Germany 
(G.D., M. Kleber, W.M.). Heart Institute, University of Sao Paulo, Brazil (N.E.D., 
A.C.P.). Montreal Heart Institute, OC, Canada (M.-P.D., J.-C.T.). Faculty of Med-
icine, Université de Montréal, QC, Canada (M.-P.D., J.-C.T.). Preventive and Ge-
nomic Cardiology, McGill University Health Centre, Montreal, QC, Canada 
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
Patel et al; Design and Rationale of GENIUS-CHD
Circ Genom Precis Med. 2019;12:e002470. DOI: 10.1161/CIRCGEN.119.002470 April 2019 158
(L.D., J.C.E., G.T.). Institute for Biomedicine, Eurac Research, Affiliated Institute 
of the University of Lübeck, Bolzano, Italy (L.F.). Institute for Medical Informat-
ics, Statistics, and Epidemiology (M.S.) and LIFE Research Centre for Civilization 
Diseases (M.S., A. Teren, R.B., J.T.), University of Leipzig, Germany. Department 
of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospi-
talet (C.G., T.E., R.J.). Amsterdam UMC, University of Amsterdam, Clinical and 
Experimental Cardiology, Amsterdam Cardiovascular Sciences, AMC Heart Cen-
ter, the Netherlands (C.G., A.A.M.W., C.R.B.). Department of Pharmacotherapy 
and Translational Research, Centre for Pharmacogenomics (Y.G., R.M.C.-D., 
J.A.J.) and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., 
J.A.J., C.J.P.), University of Florida, Gainesville. Centre for Experimental Medi-
cine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic 
(J.A.H., J.P.). Assistance Publique-Hôpitaux de Paris (AP-HP), Department of 
Clinical Pharmacology, Platform of Clinical Research of East Paris (URCEST-
CRCEST-CRB HUEP-UPMC), France (S.K.). Department of Cardio-Thoracic Sur-
gery (P.K.), Department of Clinical Chemistry (L.-P.L., T.L.), Department of Cardi-
ology (K.N.), Department of Clinical Physiology (M. Kähönen), and Department 
of Cardio-Thoracic Surgery, Finnish Cardiovascular Research Center, Faculty of 
Medicine & Life Sciences (J.O.L.), University of Tampere, Finland. Department of 
Biostatistics and Epidemiology, Texas Heart Institute, Houston (V.-V.L.). Vorarl-
berg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria 
(A. Leiherer, C.H.S., H.D.). Private University of the Principality of Liechtenstein, 
Triesen (A. Leiherer, C.H.S., H.D.). Medical Central Laboratories, Feldkirch, Aus-
tria (A. Leiherer). Statistical Genomics Division, Department of Genetics (P.A. 
Lenzini, S.C.) and Cardiovascular Division, Department of Medicine (S.C.), 
Washington University School of Medicine, Saint Louis, MO. Division of Mo-
lecular and Clinical Medicine, School of Medicine, University of Dundee, Scot-
land, United Kingdom (D. Levin, I.R.M., C.C.L.). Department of Clinical Chem-
istry, Fimlab Laboratories, Tampere, Finland (L.-P.L., T.L.). Department of 
Medicine, University of Verona, Italy (N.M., D.G., O.O.). Department of Cardiol-
ogy, Heart Center (K.N.), Department of Clinical Physiology (M. Kähönen), and 
Department of Cardio-Thoracic Surgery, Heart Centre (J.O.L.), Tampere Univer-
sity Hospital, Finland. The Christchurch Heart Institute, University of Otago 
Christchurch, New Zealand (A.P.P., A.M.R., V.A.C.). Department of Medical 
Genetics (R. Ploski) and first Chair and Department of Cardiology (G.O.), Medi-
cal University of Warsaw, Poland. Department of Epidemiology, Emory Univer-
sity Rollins School of Public Health, Atlanta, GA (Y.V.S.). Amsterdam UMC, Uni-
versity of Amsterdam, Clinical Epidemiology and Biostatistics, The Netherlands 
(M.W.T.T.). Department of Biomedical Informatics (Y.V.S.) and Division of Cardi-
ology, Department of Medicine (A.S.-T., P.B.S., A.A.Q.), Emory Clinical Cardio-
vascular Research Institute, Emory University School of Medicine, Atlanta, GA. 
Department of Cellular and Molecular Medicine, Lerner Research Institute, 
Cleveland Clinic, OH (W.H.W.T., S.L.H.). Department of Cardiovascular Medi-
cine, Heart and Vascular Institute, and Centre for Clinical Genomics, Cleveland 
Clinic, OH (W.H.W.T.). Department of Cardiovascular Medicine, Centre for Mi-
crobiome and Human Health, Heart and Vascular Institute, Cleveland Clinic, OH 
(S.L.H.). Section of Gerontology and Geriatrics, Department of Internal Medi-
cine (S.T.) and Department of Cardiology (S.T., J.W.J.), Leiden University Medical 
Centre, the Netherlands. Division Heart and Lungs, Department of Cardiology, 
UMC Utrecht, University of Utrecht, the Netherlands (J.V.S.). Ruddy Canadian 
Cardiovascular Genetics Centre, University of Ottawa Heart Institute, ON, Can-
ada (R.O.V., R.M., A.F.R.S.). Department of Biochemistry, Microbiology and Im-
munology (R.O.V., A.F.R.S.) and Departments of Medicine and Biochemistry, 
Microbiology and Immunology(R.M.), University of Ottawa, ON, Canada. De-
partment of Cardiovascular Medicine, Humanitas Clinical and Research Centre, 
Milan, Italy (C.V.A., G.C.). Transplantation Laboratory (E.V., M.-L.L.) and Heart 
and Lung Centre (J.S.), Helsinki University Hospital and University of Helsinki, 
Finland. University Medical Centre, University of Groningen, the Netherlands 
(L.A.A., P.V.d.H.). University of Texas School of Public Health, Houston(E.B.). 
Clinica Mediterranea, Naples, Italy (C.B.). Cardiology Division, Department of 
Internal Medicine (J.F.C., J.B.M., J.L.A.) and Department of Biomedical Infor-
matics (B.D.H.), University of Utah, Salt Lake City. QMRI, Cardiovascular Sci-
ences, University of Edinburgh, United Kingdom (K.F.C.). The University of Ed-
inburgh, United Kingdom (K.A.A.F). ATS Sardegna, ASSL Nuoro—Ospedale San 
Francesco, Nuoro, Italy (G.C.). William Harvey Research Institute, Barts and the 
London Medical School (P.D) and Centre for Genomic Health (P.D.), Queen Mary 
University of London,United Kingdom. Department of Health Sciences, Univer-
sity of Leicester, United Kingdom (F.D.). Department of Cardiology, University of 
Lund, Sweden (T.E.). National Heart and Lung Institute, Imperial College and 
Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, 
London, United Kingdom (K.F.); Centro de Pesquisa Clinica, Hospital Universita-
rio, Universidade de Sao Paulo, São Paulo, Brazil (P.A. Lotufo, ). ATS Sardegna, 
ASL 3 Nuoro, Nuoro, Italy (N. Marziliano). Cardiovascular Research Center, Cen-
ter for Human Genetic Research, Massachusetts General Hospital, Boston 
(C.N.-C.). Program in Medical and Population Genetics, Broad Institute, Cam-
bridge, MA (C.N.-C.). Department of Medicine and Cardiology, Academic 
Teaching Hospital Feldkirch, Austria (C.H.S.). Heart Centre Leipzig, Germany (A. 
Teren). Respiratory Oncology Unit, Department of Respiratory Medicine, Univer-
sity Hospitals KU Leuven, Belgium (E.W.). Princess Al-Jawhara Al-Brahim Centre 
of Excellence in Research of Hereditary Disorders, Jeddah, Saudi Arabia 
(A.A.M.W.). Robertson Centre for Biostatistics, University of Glasgow, United 
Kingdom (I.F.). Institute of Cardiovascular and Medical Sciences, University of 
Glasgow, United Kingdom (D.J.S., N.S.). Division Laboratories, Pharmacy, and 
Biomedical Genetics, Laboratory of Clinical Chemistry and Hematology 
(S.W.v.d.L.), Department of Neurology and Neurosurgery, Brain Centre Rudolf 
Magnus and Julius Centre for Health Sciences and Primary Care (A. Algra), Ju-
lius Center for Health Sciences and Primary Care (M.B., D.E.G., Y.v.d.G.) and 
Department of Vascular Medicine (F.L.J.V), UMC Utrecht, Utrecht University, the 
Netherlands. CNR Institute of Clinical Physiology, Pisa (M.G.A, C.C). Cardiology 
Department, Parma University Hospital, Italy (D.A.). Centre de recherche de 
l’Institut Universitaire de cardiologie et de pneumologie de Québec, Canada 
(B.J.A.). Department of Medicine, Faculty of Medicine, Université Laval, QC, 
Canada (B.J.A.); St Antonius Hospital, Department Cardiology, Nieuwegein, the 
Netherlands (T.O.B., B.K.M., J.M.t.B.). Department of Anesthesia, Critical Care 
& Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA (S.B.). De-
partment of Cardiology, Erasmus MC, Thoraxcenter (E.H.B., J.J.B.). Cardiovas-
cular Research School, Erasmus Medical Center (COEUR), Rotterdam, the 
Netherlands(E.H.B.). Laval University, Institute universitaire de cardiologie et de 
pneumologie de Québec, Canada (P.B.). Network Aging Research (NAR), Uni-
versity of Heidelberg (H.B.). Institute of Clinical Chemistry and Laboratory Med-
icine, University Hospital Regensburg, Germany (R.B.). Department of Biomedi-
cal Sciences, Humanitas University, Milan, Italy (G.C.). Assistance 
Publique-Hôpitaux de Paris (AP-HP), Department of Cardiology, Hôpital Euro-
péen Georges Pompidou & FACT (French Alliance For Cardiovascular Trials), 
Université Paris Descartes, France (N.D.). Université Paris-Descartes, France 
(N.D.). Heart Health Research Group, University of Auckland, New Zealand 
(R.N.D.). Drexel University College of Medicine, Philadelphia PA (H.D.). Division 
of Cardiology, Department of Medicine, Royal Victoria Hospital, McGill Univ 
Health Centre, Montreal, QC, Canada (J.C.E., G.T.). Department of Cardiology, 
Uppsala Clinical Research Centre, Uppsala University, Sweden (E.H.). Depart-
ment of Vascular Medicine, Academic Medical Centre, Amsterdam (G.K.H.). 
Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden 
(J.W.J.). Interuniversity Cardiology Institute of the Netherlands, Utrecht (J.W.J.). 
Department of Internal Medicine, Jagiellonian University Medical College, 
Kraków, Poland (M.P.K., M.S., W.S). Cardiology Centre, Institute for Clinical and 
Experimental Medicine, Prague, Czech Republic (J.K.). Department of Cardiol-
ogy and Internal Diseases, Military Institute of Medicine, Warsaw, Poland (M. 
Kiliszek). Department of Respiratory Medicine, Academic Medical Centre, Uni-
versity of Amsterdam (A.H.M.-v.d.Z.). Department of Internal Medicine, Skåne 
University Hospital, Malmö, Sweden (O.M.). Department of Forensic Medicine; 
Medical University of Bialystok (A.N.-J.). Pat Macpherson Centre for Pharmaco-
genetics and Pharmacogenomics, Division of Molecular and Clinical Medicine, 
Ninewells Hospital and Medical School, Dundee (C.N.P.). Department of Medi-
cine, McGill University Health Centre, Montreal, QC, Canada (L.P., J.M.B.). Car-
diovascular Research Institute, National University of Singapore (A.M.R.). Assis-
tance Publique-Hôpitaux de Paris (AP-HP), Department of Clinical Pharmacology, 
Platform of Clinical Research of East Paris (URCEST-CRCEST-CRB HUEP-UPMC), 
FACT (French Alliance for Cardiovascular Trials), Sorbonne Université (T.S.). 
Paris-Sorbonne University, UPMC-Site St Antoine, France (T.S.). Department of 
Cardiology, Clinical Sciences, Lund University, Skåne University Hospital (J.G.S.). 
Wallenberg Centre for Molecular Medicine, Lund University Diabetes Centre, 
Lund University, Sweden (J.G.S.). Program in Medical and Population Genetics, 
Broad Institute, Cambridge, MA (J.G.S.). Saint Luke’s Mid America Heart Insti-
tute, University of Missouri-Kansas City (J.A.S.). Saint Luke’s Mid America Heart 
Insti Kansas City, MO (J.A.S.). Department of Clinical Biochemistry, Copenha-
gen University Hospital, Gentofte (S.S.). Department of Cardiology, The Heart 
Centre, Copenhagen University Hospital, Rigshospitalet (J.T.-H.). Department of 
Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen, Den-
mark (J.T.-Hansen). Institute of Laboratory Medicine, Clinical Chemistry and 
Molecular Diagnostics, University Hospital, Leipzig, Germany (J.T.). Unit of Epi-
demiology and Biostatistics, Department of Health Science and Technology, 
Aalborg University Hospital, Denmark (C.T.-Pedersen). Department of Cardio-
vascular Medicine, University of Münster, Germany (J.W.). Department of Car-
diology, Herlev and Gentofte Hospital, Hellerup, Denmark (P.E.W.). Department 
of Pathology and Molecular Medicine, McMaster University (G.P.). Population 
Health Research Institute, Hamilton, ON, Canada (G.P.). Synlab Academy, Syn-
lab Holding Deutschland GmbH, Mannheim, Germany (W.M.). Clinical Institute 
of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
Patel et al; Design and Rationale of GENIUS-CHD
Circ Genom Precis Med. 2019;12:e002470. DOI: 10.1161/CIRCGEN.119.002470 April 2019 159
Austria (W.M.). Durrer Centre of Cardiogenetic Research, ICIN-Netherlands 
Heart Institute, Utrecht (F.W.A.).
Acknowledgments
The GENIUS-CHD collaborators would like to express their immense gratitude 
to all patients who participated in each of the individual studies as well as the 
many personnel who helped with recruitment, collection, curation, manage-
ment, and processing of the samples and data.
Sources of Funding
The funder(s) of the study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. Within GENIUS-CHD, all 
participating investigators and sponsors who contributed data and analyses 
are acknowledged irrespective of academic or industry affiliations. Specific 
funding statements: Dr Patel is funded by a British Heart Foundation Interme-
diate Fellowship (FS/14/76/30933). This research was also supported by the 
National Institute for Health Research University College London Hospitals Bio-
medical Research Center; Dr Schmidt is funded by BHF grant PG/18/5033837; 
Dr Holmes works in a unit that receives funding from the UK Medical Research 
Council and is supported by a British Heart Foundation Intermediate Clinical 
Research Fellowship (FS/18/23/33512) and the National Institute for Health 
Research Oxford Biomedical Research Center; The AGNES study (Arrhythmia 
Genetics in The Netherlands) was supported by research grants from the Neth-
erlands Heart Foundation (2001D019, 2003T302, 2007B202, and the PRE-
DICT project [CVON 2012-10]), the Leducq Foundation (grant 05-CVD) and 
the Center for Translational Molecular Medicine (CTMM COHFAR).; The Cleve-
land Clinic Genebank Study was supported in part by NIH grants R0133169, 
R01ES021801, R01MD010358, and R01ES025786, R01HL103866, 
R01DK106000, R01HL126827, P20HL113452, P01HL098055, P01HL076491, 
and R01HL103931; The Clinical Cohorts in Coronary disease Collaboration 
(4C) study was supported in part by National Institute for Health Research 
(NIHR) and Barts Charity; The Corogene study was supported by grants from 
Aarno Koskelo Foundation, Helsinki University Central Hospital special govern-
ment funds (EVO nos. TYH7215, TKK2012005, TYH2012209, and 
TYH2014312), and Finnish Foundation for Cardiovascular research; CABGe-
nomics was supported by Stanton Shernan, C. David Collard, Amanda A. Fox/
R01 HL 098601 National Heart, Lung, and Blood Institute (NHLBI); The Coro-
nary Disease Cohort Study (CDCS) & Post Myocardial Infarction study (PMI) 
were funded by the Health Research Council and Heart Foundation of New 
Zealand; Dr Samman-Tahnan is supported by the National Institutes of Health/
National Institutes of Aging grant AG051633; Dr Sandesara is supported by 
the Abraham J. & Phyllis Katz Foundation (Atlanta, GA); The Emory Cardiovas-
cular Biobank is supported by National Institutes of Health (NIH) grants 
5P01HL101398-02, 1P20HL113451-01, 1R56HL126558-01, 1RF-
1AG051633-01, R01 NS064162-01, R01 HL89650-01, HL095479-01, 
1U10HL110302-01, 1DP3DK094346-01, and 2P01HL086773-06A1; The Esto-
nian Biobank was funded by EU H2020 grant 692145, Estonian Research 
Council Grant IUT20-60, IUT24-6, PUT1660, PUT735, and European Union 
through the European Regional Development Fund Project No. 2014-
2020.4.01.15-0012 GENTRANSMED, NIH-GIANT, ERA-CVD grant Detectin-HF 
and 2R01DK075787-06A1; FAST-MI (French Registry of Acute ST-Elevation or 
non–ST-elevation Myocardial Infarction) 2005 is a registry of the French Society 
of Cardiology, supported by unrestricted grants from Pfizer and Servier. Addi-
tional support was obtained from a research grant from the French Caisse 
Nationale d’Assurance Maladie; GENESIS-PRAXY is funded by the Canadian 
Institutes of Health Research and Heart and Stroke Foundations of Alberta, 
NWT & Nunavut, British Columbia and Yukon, Nova Scotia, Ontario, and Que-
bec (HSFC); The GENDEMIP study was supported by Project (MH, Czech Re-
public) No. 00023001 (ICEM, Prague); GoDARTS was funded by the Wellcome 
Trust (072960/Z/03/Z, 084726/Z/08/Z, 084727/Z/08/Z, 085475/Z/08/Z, and 
085475/B/08/Z) and as part of the EU IMI-SUMMIT programme. Dr Palmer has 
received grant funding from the Wellcome Trust to develop the GoDARTS co-
hort; Dr Mordi is supported by an NHS Education of Scotland/Chief Scientist 
Office Postdoctoral Clinical Lectureship (PCL 17/07); the GENECOR study was 
supported in part by the Italian Ministry of Research’s Fund for Basic Research 
(FIRB 2005); GRACE UK was supported in part by an Educational Grant from 
Sanofi Aventis; Award from Chief Scientist Office, Scotland; INVEST-GENES 
was supported by the National Institute of Health Pharmacogenomics Re-
search Network grant U01-GM074492, NIH R01 HL074730, University of 
Florida Opportunity Fund, BASF Pharma and Abbott Laboratories; IATVB was 
supported by Epidemiologia e Genetica della Morte Improvvisa in Sardegna; 
The KAROLA study has received financial support by the German Ministry of 
Education and Research (01GD9820/0 and 01ER0814), by the Willy-Robert-
Pitzer Foundation, and by the Waldburg-Zeil Clinics Isny; The KRAKOW GE-
NIUS Study was supported by a grant from the Polish Ministry of Science and 
Higher Education, no. NN402083939 and the National Science Centre, no. 
2013/09/B/NZ5/00770; LIFE-Heart was funded by the Leipzig Research Center 
for Civilization Diseases (LIFE). LIFE is an organizational unit affiliated to the 
Medical Faculty of the University of Leipzig. LIFE is funded by means of the 
European Union, by the European Regional Development Fund (ERDF) and by 
funds of the Free State of Saxony within the framework of the excellence ini-
tiative; The LURIC study was supported by the 7th Framework Program (Ath-
eroRemo, grant agreement number 201668 and RiskyCAD, grant agreement 
number 305739) of the European Union; Dr Smith was supported by grants 
from the European Research Council, Swedish Heart-Lung Foundation, the 
Swedish Research Council, the Crafoord Foundation, governmental funding of 
clinical research within the Swedish National Health Service, Skåne University 
Hospital in Lund, and the Scania county, a generous donation from the Knut 
and Alice Wallenberg foundation to the Wallenberg Center for Molecular 
Medicine at Lund University, and funding from the Swedish Research Council 
and Swedish Foundation for Strategic Research to the Lund University Diabetes 
Center; The NEAPOLIS CAMPANIA study was suppported by European Re-
search Council Advanced Grant (CardioEpigen, no. 294609); Italian Ministry of 
Health (PE-2013-02356818); Italian Ministry of Education, University and Re-
search (2015583WMX); The North East Poland Myocardial Infarction Study 
was supported by grant no. 402 529139 from the National Science Center 
(Poland); Dr Vilmundarson is supported by a graduate fellowship of the Univer-
sity of Ottawa Heart Institute; OHGS was funded in part by a Heart and Stroke 
Foundation grant; Dr Stott was supported in part by an investgator initiated 
grant from Bristol Myers Squibb; The PROSPER study was supported by an in-
vestigator initiated grant obtained from Bristol-Myers Squibb. Dr Jukema is an 
Established Clinical Investigator of the Netherlands Heart Foundation (grant 
2001 D 032). Support for genotyping was provided by the seventh framework 
program of the European commission (grant 223004) and by the Netherlands 
Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-
060-810).; The RISCA study was supported in part by FRSQ, HSFC, Merck Frost 
Canada, Pfizer Canada; The SHEEP study was supported by grants from the 
Swedish Council for Work Life and Social Research, and the Stockholm Coun-
ty Council; The TNT trial was sponsored by Pfizer who granted access to data, 
Genotyping of the samples was funded in part by grants from Genome Cana-
da and Genome Quebec and the Canadian Institutes of Health Research 
(CIHR); Dr Arsenault holds a junior scholar award from the Fonds de recherche 
du Quebec-Sante (FRQS); Dr Cresci is supported, in part, by the National Insti-
tutes of Health (Cresci R01 NR013396). The TRIUMPH study was sponsored by 
the National Institutes of Health: Washington University School of Medicine 
SCCOR Grant P50 HL077113; The UCP studies were funded by the Nether-
lands Heart Foundation and the Dutch Top Institute Pharma Mondriaan Proj-
ect; The Verona Heart Study was supported by the Cariverona Foundation; 
Veneto Region; Italian Ministry of Education, University, and Research (MIUR); 
LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University 
of Verona; The Warsaw ACS Registry is supported by grant No. R13 0001 06 
from The National Centre for Research and Development (NCBiR), Statutory 
Grant from Medical University of Warsaw; Dr Nelson is funded by the British 
Heart Foundation; Dr Samani is funded by the British Heart Foundation and is 
a NIHR Senior Investigator; Dr Hingorani is a NIHR Senior Investigator. Dr As-
selbergs is supported by UCL Hospitals NIHR Biomedical Research Centre, EU/
EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant 
no. 116074, the European Union’s Horizon 2020 research and innovation pro-
gramme under the ERA-NET Co-fund action No. 01KL1802 (Druggable-MI-
gene) jointly funded by the Dutch Heart Foundation and Netherlands Organi-
zation for Health Research and Development (ZonMw).
Disclosures
Dr Patel has received speaker fees and honoraria from Amgen, Sanofi, and 
Bayer and research funding from Regeneron; Dr Holmes has collaborated with 
Boehringer Ingelheim in research, and in accordance with the policy of the The 
Clinical Trial Service Unit and Epidemiological Studies Unit (University of Ox-
ford), did not accept any personal payment; Dr Akerblom has received institu-
tional research grant and speakers fee from AstraZeneca, institutional research 
grant from Roche Diagnostics; Dr James has received grants from AstraZen-
eca, The Medicines Company, Swedish heart and lung foundation, Swedish 
research council, Janssen; personal fees from Bayer; Dr Hagstrom declares be-
ing an expert committee member, lecture fees, and institutional research grant 
from Sanofi, and Amgen; institutional research grants from AstraZeneca, and 
GlaxoSmithKline; expert committee member and lecture fees NovoNordisk and 
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
Patel et al; Design and Rationale of GENIUS-CHD
Circ Genom Precis Med. 2019;12:e002470. DOI: 10.1161/CIRCGEN.119.002470 April 2019 160
Behringer; Dr Held declares institutional research grant, advisory board mem-
ber and speaker’s bureau from AstraZeneca; institutional research grants from 
Bristol-Myers Squibb Merck & Co, GlaxoSmithKline, Roche Diagnostics. Advi-
sory board for Bayer and Boehringer Ingelheim; Dr Lindholm has received insti-
tutional research grants from AstraZeneca, and GlaxoSmithKline; Speaker fees 
from AstraZeneca, Speaker fees from AstraZeneca; Dr Siegbahn has received 
institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-
Myers Squibb/Pfizer, Roche Diagnostics, GlaxoSmithKline; Dr ten Berg reports 
receiving fees for board membership from AstraZeneca, consulting fees from 
AstraZeneca, Eli Lilly, and Merck, and lecture fees from Daiichi Sankyo and Eli 
Lilly, AstraZeneca, Sanofi and Accumetrics; Dr Wallentin reports institutional 
research grants, consultancy fees, lecture fees, and travel support from Bristol-
Myers Squibb/Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim; in-
stitutional research grants from Merck & Co, Roche Diagnostics; consultancy 
fees from Abbott; and holds a patent EP2047275B1 licensed to Roche Diagnos-
tics, and a patent US8951742B2 licensed to Roche Diagnostics; Dr Asselbergs 
has received research funding from Regeneron, Pfizer, Sanofi.
REFERENCES
 1. Ford ES, et al. Proportion of the decline in cardiovascular mortal-
ity disease due to prevention versus treatment: public health versus 
clinical care. Annu Rev Public Health. 2011;32:5–22. doi: 10.1146/ 
annurev-publhealth-031210-101211
 2. Sidney S, et al. Recent trends in cardiovascular mortality in the united 
states and public health goals. JAMA Cardiol. 2016;1:594–599. doi: 
10.1001/jamacardio.2016.1326
 3. Ford ES, et al. Explaining the decrease in U.S. deaths from coro-
nary disease, 1980-2000. N Engl J Med. 2007;356:2388–2398. doi: 
10.1056/NEJMsa053935
 4. Benjamin EJ, et al.; American Heart Association Statistics Committee and 
Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 
Update: a report from the American Heart Association. Circulation. 
2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485
 5. Scarborough PBP, et al. Coronary Heart Disease Statistics 2010 Edition. 
London: British Heart Foundation; 2010.
 6. Yusuf S, et al.; Interheart Study Investigators. Effect of potentially modifi-
able risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet. 2004;364:937–952. doi: 
10.1016/S0140-6736(04)17018-9
 7. Deloukas P, et al. Large-scale association analysis identifies new risk loci 
for coronary artery disease. Nat Genet. 2013;45:25–33.
 8. Fox KA, et al. Prediction of risk of death and myocardial infarction in the 
six months after presentation with acute coronary syndrome: prospective 
multinational observational study (GRACE). BMJ. 2006;333:1091. doi: 
10.1136/bmj.38985.646481.55
 9. Schiele F, et al. Coronary artery disease: risk stratification and patient 
selection for more aggressive secondary prevention. Eur J Prev Cardiol. 
2017;24(3_suppl):88–100. doi: 10.1177/2047487317706586
 10. Schwartz GG, et al.; dal-OUTCOMES Investigators. Effects of dalcetra-
pib in patients with a recent acute coronary syndrome. N Engl J Med. 
2012;367:2089–2099. doi: 10.1056/NEJMoa1206797
 11. White HD, et al. Darapladib for preventing ischemic events in stable coro-
nary heart disease. N Engl J Med. 2014;370:1702–1711.
 12. Boden WE, et al. Niacin in patients with low HDL cholesterol levels receiv-
ing intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
 13. Armitage JM, et al. Effects of homocysteine-lowering with folic acid 
plus vitamin B12 vs placebo on mortality and major morbidity in 
myocardial infarction survivors: a randomized trial. JAMA. 2010;303: 
2486–2494.
 14. Global BMIMC, et al. Body-mass index and all-cause mortality: individual-
participant-data meta-analysis of 239 prospective studies in four conti-
nents. Lancet. 2016;388:776–786.
 15. Wang ZJ, et al. Association of body mass index with mortality and 
cardiovascular events for patients with coronary artery disease: a sys-
tematic review and meta-analysis. Heart. 2015;101:1631–1638. doi: 
10.1136/heartjnl-2014-307119
 16. Cannon CP, et al.; Improve-IT Investigators. Ezetimibe added to statin 
therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–
2397. doi: 10.1056/NEJMoa1410489
 17. Sabatine MS, et al.; Fourier Steering Committee and Investigators. Evo-
locumab and clinical outcomes in patients with cardiovascular disease. N 
Engl J Med. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664
 18. Ridker PM, et al.; Cantos Trial Group. Antiinflammatory therapy with 
canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–
1131. doi: 10.1056/NEJMoa1707914
 19. Patel RS, et al. The Genius-CHD consortium. Eur Heart J. 2015;36:2674–2676.
 20. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: 
Lippincott-Raven, 1998.
 21. Lee JC, et al.; UK IBD Genetics Consortium. Genome-wide associa-
tion study identifies distinct genetic contributions to prognosis and 
susceptibility in Crohn’s disease. Nat Genet. 2017;49:262–268. doi: 
10.1038/ng.3755
 22. Ohman EM, et al.; Reach Registry Investigators. The Reduction of Athero-
thrombosis for Continued Health (REACH) registry: an international, pro-
spective, observational investigation in subjects at risk for atherothrom-
botic events-study design. Am Heart J. 2006;151:786.e1–786.e10. doi: 
10.1016/j.ahj.2005.11.004
 23. Psaty BM, et al. The Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium as a model of collaborative science. 
Epidemiology. 2013;24:346–348. doi: 10.1097/EDE.0b013e31828b2cbb
 24. Collins R, et al. What makes UK Biobank special? Lancet. 2012;379:1173–
1174. doi: 10.1016/S0140-6736(12)60404-8
 25. Chen Z, et al.; China Kadoorie Biobank (CKB) collaborative group. China 
Kadoorie Biobank of 0.5 million people: survey methods, baseline char-
acteristics and long-term follow-up. Int J Epidemiol. 2011;40:1652–1666. 
doi: 10.1093/ije/dyr120
 26. Reilly MP, et al.; Myocardial Infarction Genetics Consortium; Well-
come Trust Case Control Consortium. Identification of ADAMTS7 as a 
novel locus for coronary atherosclerosis and association of ABO with 
myocardial infarction in the presence of coronary atherosclerosis: two 
genome-wide association studies. Lancet. 2011;377:383–392. doi: 
10.1016/S0140-6736(10)61996-4
 27. Dahabreh IJ, et al. Index event bias as an explanation for the para-
doxes of recurrence risk research. JAMA. 2011;305:822–823. doi: 
10.1001/jama.2011.163
 28. Nicholls SJ, et al. Effect of evolocumab on progression of coronary dis-
ease in statin-treated patients: the glagov randomized clinical trial. JAMA. 
2016;316:2373–2384. doi: 10.1001/jama.2016.16951
 29. Hu YJ, et al. Impact of selection bias on estimation of subsequent event 
risk. Circ Cardiovasc Genet. 2017;10:001616
D
ow
nloaded from
 http://ahajournals.org by on July 31, 2019
